Skip to main content
. 2021 Jun 22;90(3):477–489. doi: 10.1002/ana.26137

TABLE 3.

Multivariable Models for Dose‐dependent Effects of IgMIF and IgGIF in OCGB+/IgGIF +/IgMIF + Patients for the Following Outcomes: (A) Time to First Relapse, (B) sNfL Z‐scores, (C) sNfL Z‐scores in Untreated Patients, (D) Total T2w Lesion Count, (E) New/Enlarging T2w lesion count, (F) Multiple Sclerosis Severity Score and (G) Time to First Initiation of a heDMT

A. Time to First Relapse HR CI p
1. IgMIF (> vs <median) 1.85 1.17, 2.92 <0.01
2. IgGIF (> vs <median) 1.13 0.73,1.75 0.578
3. IgMIF (per 1%) 1.01 1.00,1.02 0.064
4. IgGIF (per 1%) 1.01 1.00,1.02 0.180
B. sNfL Z‐scores (n = 716) Est. CI p
1. IgMIF (> vs <median) 0.43 0.10,0.77 0.013
2. IgGIF (> vs <median) 0.01 −0.32, 0.34 0.951
3. IgMIF (per 1%) 0.01 0.00, 0.02 0.034
4. IgGIF (per 1%) 0.00 −0.01, 0.01 0.909
C. sNfL Z‐scores in untreated patients (n = 88) Est. CI p
1. IgMIF (> vs <median) 0.92 0.18, 1.66 0.019
2. IgGIF (> vs <median) −0.15 −0.88, 0.59 0.696
3. IgMIF (per 1%) 0.02 0.00, 0.04 0.032
4. IgGIF (per 1%) 0.00 −0.02, 0.02 0.855
D. T2w Lesion Count (n = 414) HR CI p
1. IgMIF (> vs <median) 1.63 0.96, 2.75 0.071
2. IgGIF (> vs <median) 1.02 0.61, 1.72 0.940
3. IgMIF (per 1%) 1.01 1.00, 1.02 0.271
4. IgGIF (per 1%) 1.01 0.99, 1.02 0.385
E. New/Enlarging T2w Lesion Count (n = 195) HR CI p
1. IgMIF (> vs <median) 2.86 1.25, 6.54 0.013
2. IgGIF (> vs <median) 1.04 0.49, 2.20 0.913
3. IgMIF (per 1%) 1.02 1.01, 1.02 <0.01
4. IgGIF (per 1%) 1.00 1.00, 1.01 0.417
F. Multiple Sclerosis Severity Score (n = 111) HR CI p
1. IgMIF (> vs <median) 0.59 −0.23, 1.40 0.156
2. IgGIF (> vs <median) −0.08 −0.87, 0.71 0.843
3. IgMIF (per 1%) 0.01 −0.01, 0.03 0.201
4. IgGIF (per 1%) 0.00 −0.01, 0.02 0.680
G. Time to First Initiation of an heDMT (n = 111) HR CI p
1. IgMIF (> vs <median) 2.35 1.33, 4.16 <0.01
2. IgGIF (> vs <median) 0.87 0.51, 1.48 0.603
3. IgMIF (per 1%) 1.02 1.01, 1.03 <0.01
4. IgGIF (per 1%) 1.000 0.99, 1.01 0.944

Lines 1 and 2: Model 1: IgMIF and IgGIF split by median. Lines 3 and 4: Model 2: IgMIF and IgGIF as continuous variables.

CI = 95% confidence interval; heDMT = high‐efficacy disease‐modifying treatment; HR = hazard ratio; IgGIF/MIF = immunoglobulin G/M intrathecal fraction; OCGB+ = presence of oligoclonal IgG bands.